J.P. Morgan Maintains Overweight Rating on Ariad Pharmaceuticals

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

According to J.P. Morgan, Ariad Pharmaceuticals (NASDAQ: ARIA) Overweight rating is maintained.J.P. Morgan said that it is attending the 2011 ASH conference in San Diego, where interim data were presented on Sunday afternoon for the pivotal PACE trial evaluating ponatinib in chronic myeloid leukemia (CML) patients. “The bottom line is that so far PACE looks as if it is on track to be a successful trial with trends reminiscent of the Ph1 data. Reiterate OW.”Ariad Pharmaceuticals closed on Friday at $11.63.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!